denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Hematology Disease Topics & Pathways:
Research, Non-Biological therapies, Chemotherapy, Clinical Research, Chronic Myeloid Malignancies, Diseases, Therapies, Myeloid Malignancies, Study Population, Human
Description:
Despite most chronic phase (CP-) CML patients achieving excellent outcomes with tyrosine kinase inhibitor (TKI) therapy there are still complex challenges confronting the clinician. In this session we will cover three of these specific challenges. For the patient who doesn’t respond well to front-line or second-line therapy further lines of TKI therapy are now available that may still achieve long-term disease control. In some cases, allogeneic stem cell transplantation (allo-HSCT) will need to be considered, to determine whether it provides the best prospect of long-term survival. Many younger women with CP-CML are now incorporating plans to raise a family when they are making treatment decisions. This is now a realistic and relatively safe consideration in women responding well to TKI therapy.
Dr Timothy Hughes will discuss the appropriate assessments that are needed in CP-CML patients being considered for a change in therapeutic approach because of TKI resistance. The choice of optimal TKI and TKI dose for a CP-CML patient with TKI resistance needs to be considered in the context of their prior response and tolerance, mutation profile, co-morbidities, and cardiovascular risk factors. This talk will outline strategies to integrate all these factors to assist in making the best recommendations for the patient to consider.
Dr Nicolaus Kroeger will discuss the challenge of integrating allo-HSCT as a curative treatment approach for chronic and advanced phases of CML in the treatment beyond frontline therapy. Despite lack of prospective randomised trials, the lecture will provide current results, Pros and Cons and international recommendations regarding allo-HSCT which are supportive and helpful for patient counselling and decision making.
Dr Jane Apperley will address an issue of considerable importance to patients with CML who are of child-bearing age, namely the safety of planned or unplanned pregnancies. She will discuss the management of patients who present during pregnancy, and then of those with established disease who wish to have a child. Decision-making requires sensitive consideration of the competing risks to patient and infant, and involvement of multi-disciplinary teams.
Dr Timothy Hughes will discuss the appropriate assessments that are needed in CP-CML patients being considered for a change in therapeutic approach because of TKI resistance. The choice of optimal TKI and TKI dose for a CP-CML patient with TKI resistance needs to be considered in the context of their prior response and tolerance, mutation profile, co-morbidities, and cardiovascular risk factors. This talk will outline strategies to integrate all these factors to assist in making the best recommendations for the patient to consider.
Dr Nicolaus Kroeger will discuss the challenge of integrating allo-HSCT as a curative treatment approach for chronic and advanced phases of CML in the treatment beyond frontline therapy. Despite lack of prospective randomised trials, the lecture will provide current results, Pros and Cons and international recommendations regarding allo-HSCT which are supportive and helpful for patient counselling and decision making.
Dr Jane Apperley will address an issue of considerable importance to patients with CML who are of child-bearing age, namely the safety of planned or unplanned pregnancies. She will discuss the management of patients who present during pregnancy, and then of those with established disease who wish to have a child. Decision-making requires sensitive consideration of the competing risks to patient and infant, and involvement of multi-disciplinary teams.